Brett Charles Plyler, M.D.
25 E Washington St. Suite 1805
Chicago, IL 60602
312 782 5959

Employment

2008-Present	**Northwestern Memorial Hospital.** Instructor for second year residents' psychotherapy class and individual resident supervision. Chicago IL.
2006-Present	**Chicago Research Center, Inc.** 3401 N. Central Ave. Chicago IL 60634 Investigator
2004- Present	**Private Practice.** Outpatient/Inpatient and psychotherapy/psychopharmacology. Chicago IL.
2006- 2008	**Northwestern Memorial Hospital.** Attending psychiatrist for inpatients. Chicago IL.
2004-2005	**Cook County Jail.** Staff psychiatrist for inpatients. Chicago, IL.
2004-2005	**Family Alliance.** Outpatient geriatric treatment. Woodstock, IL.
2001-2005	**Oak Forest Psychological Services.** Conducted group psychotherapy. Chicago, IL.
2000-2001	**Lakeshore Mental Health Institute.** Staff physician responsible for medical and psychiatric problems of inpatient population. Knoxville, TN.
2000-2001	**Jellico Community Hospital.** Emergency room physician. Jellico, TN.
2000-2001	**East Tennessee Medical Group.** Staff physician for an urgent care clinic. Maryville, TN.
1999-2001	**Peninsula Psychiatric Hospital.** Staff physician responsible for involuntary commitments. Knoxville, TN.

Education

2006	**Board Certification Adult General Psychiatry.**
2004- Present	**Adult Psychodynamic Psychotherapy Program.** Institute for Psychoanalysis. Chicago IL.
2001-2004	**Rush St. Luke's Presbyterian Medical Center.** **G**eneral Psychiatry Residency program. Chicago IL.

Education

2003-2004	**Rush St. Luke's Presbyterian Medical Center.** Chief Resident of General Psychiatry program.
2002	**Board Certification Family Practice.**
1998-2001	**University of Tennessee Medical Center at Knoxville**. Family Practice residency program.
1994-1998	**University of Tennessee, Memphis, School of Medicine.** M.D.
1989-1994	**University of Tennessee, Knoxville.** B.A., College Scholars (Psychology and History).

Research

A Multicenter, Randomized, 8-Week, Double-Blind, Placebo-Controlled Study Followed By a 6-Month Open-Label Extension To Evaluate The Efficacy and Safety of DVS SR in Peri – and Postmenopausal Women With Major Depressive Disorder, Protocol# 315A1-403-WW, Wyeth, 2006 ***Principal Investigator***

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Sustained-release Quetiapine Fumarate (SEROQUEL®) Compared with Placebo in the Treatment of Generalized Anxiety Disorder, Protocol# D1448C00009, AstraZeneca, 2006 ***Principal Investigator***

A Randomized, Double-Blind, Placebo Controlled Study of the Efficacy of PRX-0023 in Patients With Major Depressive Disorder, Protocol# EPX-CP-020, Epix, 2007 ***Principal Investigator***

A Multicenter, Multiple Dose, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of AGN 203818 in Female Patients With Fibromyalgia Syndrome, Protocol# 203818-503-00, Allergan 2007 ***Principal Investigator***

A Multicenter, Randomized, Double-blind, Parallel-group, Placebocontrolled Study of the Efficacy and Safety of Quetiapine Fumarate Extended-Release (SEROQUEL® XR) Compared with Placebo as an Adjunct to Treatment in Patients with Generalized Anxiety Disorder who Demonstrate Partial or No Response to a Selective Serotonin Reuptake Inhibitor or Serotonin-Norepinephrine Reuptake Inhibitor Alone or in Combination with a Benzodiazepine, Protocol# D1441L00016, Astra Zeneca 2007 ***Principal Investigator***

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 (20mg/day and 50 mg/day) in the Treatment of Primary Insomnia, Protocol# VP-VEC-162-3104, Vanda 2007 ***Sub Investigator***

A Phase III Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of MK-0431A in Patients with Type 2 Diabetes Mellitus, Protocol# 097-00, Merck 2007 ***Sub Investigator***

A double-blind, randomized, parallel group, placebo-controlled sleep laboratory efficacy and safety study with Org 50081 in elderly subjects with chronic primary insomnia, Protocol# 21108, Organon 2007 ***Sub Investigator***

Research

Efficacy and safety of 2 mg/day M100907 on Sleep Maintenance Insomnia: a 6-week, multicenter, randomized, double-blind, placebo-controlled Polysomnographic study, Protocol# EFC6072, Sanofi-Aventis 2007 ***Sub Investigator***

A six-week, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Efficacy and Safety, Sleep Lab Trial With Org 50081 in Patients With Chronic Primary Insomnia, Protocol# 176002, Organon, 2007 ***Sub Investigator***

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of MAP0004 in Adult Migraineurs for a Single Migraine Followed by Open -Label Extensions to 26/52 Weeks, Protocol # MAP0004-CL P301, Map 2007 ***Sub Investigator***

A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients with Major Depressive Disorder, Protocol# CLDA-07-DP-04, PGXHealth 2007 ***Principal Investigator***

Open-label Multi-center Safety Trial of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain, Protocol# INS-06-007, Insys Therapeutics 2007 ***Sub Investigator***

A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of TAK-491 When Compared With Valsartan and Olmesartan in Subjects With Essential Hypertension, Protocol# 01-06-TL-491-019, Takeda 2008 ***Sub Investigator***

A Randomized, Double-blind, Placebo-controlled Subjective Study to Assess the Efficacy of APD125 in Patients with Primary Insomnia Characterized by Difficulty Maintaining Sleep, Protocol# APD125-007, Arena 2008 ***Sub Investigator***

Efficacy and Safety of Eplivanserin 5mg/day in Insomnia Characterized by Sleep Maintenance Difficulties: a 6-week, Randomized, Double-Blind, Placebo-Controlled, Polysomnography Study, Protocol# EFC10844/ECLIPSE, Sanofi-Aventis 2008 ***Sub Investigator***

A Phase IIb, Multicenter, Randomized, Double-Blind Placebo-Controlled, 2-period Adaptive Crossover Polysomnography Study to Evaluate the Safety and Efficacy of MK-4305 in Patients with Primary Insomnia, Protocol# MK-4305 006-00, Merck 2008 ***Sub Investigator***

A Multicenter, Multiple Dose, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of AGN 230818 in Female Patients with Fibromyalgia Syndrome Protocol #203818-503-01, Allergan 2008 ***Principal Investigator***

A 6-Month Placebo-Controlled Study Of Pagoclone 0.075 MG, 0.30 MG OR 0.60 MG Twice Daily In Adults With Stuttering, #IP456-041, Indevus 2009 ***Principal Investigator***

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Armodafinil at a Target Dosage of 200 mg/day as Treatment for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Comorbid Major Depressive Disorder or Dysthymic Disorder, Protocol # C10953/4024/ES/US, Cephalon 2008 ***Sub Investigator***

Effects of Pregabalin on Sleep Maintenance in Subjects With Fibromyalgia Syndrome nad Sleep Maintenance Disturbance: A Randomized Placebo-Controlled 2-Way Crossover Polysomnography Study, Protocol# A0081165, Pfizer 2009 ***Principal Investigator***

A Randomized, Placebo-Controlled, Double-Blind, Fixed –Dose Study of the Efficacy and Safety of Eszopiclone in Children (6 to 11 years) and Adolescents (12 to 17 years) with Attention-Deficit/Hyperactivity Disorder-Associated Insomnia, Protocol# 190-246, Sepracor 2009 ***Principal Investigator***

Research

A Long-Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 years) and Adolescents (12 to 17 years) with Attention-Deficit/Hyperactivity Disorder-Associated Insomnia, Protocol# 190-247, Sepracor 2009 ***Principal Investigator***

A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder, Protocol# LVM-MD-02, Forest 2009 ***Principal Investigator***

A Long-Term, Open-label Extension Study of F2695 SR in Adult Patients With Major Depressive Disorder. Protocol# LVM-MD-04, Forest 2009 ***Principal Investigator***

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients with Primary Insomnia. Protocol#MK4305-009, Merck 2009 ***Sub-Investigator***

A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated with Menopause. Protocol#N30-003, Noven Therapeutics 2010 ***Sub Investigator***

A 12-week, Randomized, Double-Blind, Placebo-Controlled, Phase III Safety Trial of Flibanserin Tablets (100 milligrams daily) in Women Taking a Selective Serotonin or Serotonin-Norepinephrine Reuptake Inhibitor With Decreased Sexual Desire and Distress, Protocol#511.114, Boehringer-Ingelheim 2009 ***Principal Investigator***

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse-Prevention study With F2695 SR in Patients With Major Depressive Disorder. Protocol# LVM-MD-05, Forest 2010 ***Principal Investigator***

A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy. Protocol# D4130C00002 (Flex), AstraZeneca 2010 ***Principal Investigator***

A Multicenter, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase III, Long-Term Safety and Tolerability Study of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant Therapy. Protocol# D4130C00007 (LTSS), AstraZeneca 2010 ***Principal Investigator***

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Polysomnography Study to Evaluate the Safety and Efficacy of MK-4305 in Elderly Patients with Primary Insomnia. Protocol# MK4305-0029, Merck 2010 ***Sub-Investigator***

A Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover, Multicenter Polysomnography study Of Pregabalin and Pramipexole in Adults With Restless Legs Syndrome. Protocol# A008118, Pfizer 2010 ***Sub-Investigator***

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Armodafinil Treatment (150 mg) in Improving Clinical Condition Late in the Shift and in Improving Functional and Patient-Reported Outcomes in Adult Patients With Excessive Sleepiness Associated With Shift Work Disorder. Protocol# C10953/4030, Cephalon 2010 ***Sub-Investigator***

Honors and Awards

1993	**Phi Beta Kappa.**
1990	**Phi Kappa Phi Honor Society.**
1990-1994	**College Scholars Program.** University of Tennessee, Knoxville. merit-based individualized undergraduate program of study.
1989-1993	**National Merit Scholarship.**
1989-1993	**Robert S. Wood Trustee Scholarship.** University of Tennessee, Knoxville, tuition merit scholarship.

Extracurricular

2003-Present	**Book Reviewer, Doody's Book Review Service.** Reviewed current texts on mental health prior to general publication.
1999-2000	**Camp Physician, Boy Scouts of America, Camp Buck Toms.** Responsible for healthcare of scouts and staff during summer camp.
1998-Present	**American Association of Family Physicians.**
1994-Present	**American Medical Association.**
1996-1998	**Family Practice Student Association.**